Teneligliptin,Markets and News,API,Teneligliptin,760937-92-6,ANQING CHICO PHARMACEUTICAL

Abstract

Teneligliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor used in the management of type 2 diabetes mellitus. Developed by Mitsubishi Tanabe Pharma, it was launched in Japan in 2012 under the trade name Tenelia. This paper provides an in-depth analysis of teneligliptin, covering its chemical properties, development history, approval timeline, market presence, competitive landscape, and the impact of generic formulations.

Keywords

Teneligliptin, DPP-4 inhibitor, type 2 diabetes mellitus, chemical properties, market analysis, global sales, generics.

Introduction

Teneligliptin, marketed as Tenelia, is an oral medication prescribed for the management of type 2 diabetes mellitus. As a selective DPP-4 inhibitor, it enhances insulin secretion and inhibits glucagon release, thereby improving glycemic control. Notably, teneligliptin's pharmacokinetic profile allows for once-daily dosing without the need for renal dose adjustment.

Chemical Properties

Teneligliptin has the chemical formula C22H30N6OS and a molar mass of approximately 426.58 g·mol−1. Its IUPAC name is {(2S,4S)-4-[4-(3-Methyl-1-phenyl-1H-pyrazol-5-yl)-1-piperazinyl]-2-pyrrolidinyl}(1,3-thiazolidin-3-yl)methanone. The structural design of teneligliptin contributes to its potent and selective inhibition of DPP-4, distinguishing it from other protease inhibitors.

Development and Approval Timeline

Developed by Mitsubishi Tanabe Pharma, teneligliptin was launched in Japan in September 2012 under the trade name Tenelia. It has since been approved for use in several countries, including Korea, India, and Argentina. The approval process in these regions has been facilitated by the drug's efficacy and favorable safety profile.

Time on the Market

Since its introduction in 2012, teneligliptin has been available in Japan for over a decade. Its sustained presence indicates acceptance among healthcare providers and patients, particularly for those seeking a DPP-4 inhibitor with minimal renal excretion.

Global Sales and Market Competition

While specific global sales figures for teneligliptin are not publicly disclosed, its market position is influenced by competition from other DPP-4 inhibitors such as sitagliptin, saxagliptin, and linagliptin. The diabetes medication market is characterized by a variety of treatment options, including both oral and injectable therapies, catering to diverse patient needs. Teneligliptin's unique pharmacokinetic profile, including its minimal renal excretion, differentiates it from competitors and may influence prescribing decisions.

Generics and Related Developments

The patent for teneligliptin expired in 2015, leading to the introduction of generic formulations. The availability of generics has increased accessibility and reduced costs, aligning with global efforts to make diabetes treatments more affordable. However, the influx of generic versions has intensified market competition, potentially impacting the market share of original teneligliptin products.

Speculated Sales Figures (2020–2024)

Extrapolated from CHAT GPT, combined with its network data

While exact sales data for teneligliptin from 2020 to 2024 are not publicly available, we can speculate based on market trends and available data:

• 2020: Given the global impact of the COVID-19 pandemic, the pharmaceutical market experienced disruptions. However, the demand for diabetes medications remained relatively stable. It's reasonable to estimate that teneligliptin's sales in 2020 were approximately ¥10 billion.

• 2021: As the world began to adapt to the pandemic, healthcare services normalized, leading to a slight increase in pharmaceutical sales. Teneligliptin's sales might have reached around ¥12 billion in 2021.

• 2022: With the introduction of generic versions post-patent expiration, market competition intensified. This likely led to a stabilization or slight decline in sales for the original product. Estimated sales could be approximately ¥11 billion.

• 2023: The market would have seen further penetration by generic alternatives. Original brand sales might have decreased to around ¥9 billion, with generics capturing a significant market share.

• 2024: Assuming continued growth of generic formulations and sustained competition, sales for the original teneligliptin product might have stabilized at approximately ¥8 billion.

Conclusion

Teneligliptin represents a significant advancement in the pharmacological management of type 2 diabetes mellitus. Its development, characterized by strategic chemical modifications, has resulted in a medication that offers efficacy with a favorable side effect profile. The introduction of generics has further expanded its reach, underscoring the importance of such therapies in global diabetes care. As the market evolves, teneligliptin's unique pharmacokinetic properties may continue to influence its position within the competitive landscape.

Active Pharmaceutical Ingredient
760937-92-6
Teneligliptin, (chemical grade, purity ≥99.0%) are currently supplied by our company. [Own compliance factory, fully support factory audit] For details, you can call the bottom line to get the latest price of the product!

Disclaimer:Products are only available to countries where there is no valid patent protection. Products still covered by patents rights are available exclusively for experimental or registration purpose pursuant to national applicable law, and shall be sold in strict accordance with the laws of the People's Republic of China and the laws of the Buyer's country. All products are not for human use. Buyer is obligated for evaluation of the patent situation in its domestic market and shall be held liable for uses which do not fall within the scope of the experimental or registration use exception and are not permitted by national applicable law.

References or other information:
FDA、Wikipedia、Chatgpt、DeepSeek、chemicalbook

If there is any infringement, please apologize and delete. If there are any errors, welcome to criticize and correct.
Under no circumstances shall the information or opinions expressed herein be construed as investment advice for any person.